1. Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan
- Author
-
Jee-Fu Huang, Pei-Chien Tsai, Chen-Hua Liu, Szu Jen Wang, Cheng Yuan Peng, Chih-Wen Lin, Sheng-Shun Yang, Chih-Lin Lin, Hsing Tao Kuo, Chi Yi Chen, Wei-Lun Tsai, Mei Hsuan Lee, Chih Lang Lin, Wan-Long Chuang, Ming-Lung Yu, Chia-Chi Wang, Lein Ray Mo, Chia Sheng Huang, Chou Kwok Hsiung, Chi Chieh Yang, Chia-Yen Dai, Ching Chu Lo, Chun Chao Chang, Chun Ting Chen, Ming-Jong Bair, Yi Hsiang Huang, Jui Ting Hu, Chien Neng Kao, Pin-Nan Cheng, Guei Ying Chen, Chao-Hung Hung, Chung Feng Huang, Tsai Yuan Hsieh, Kuo Chih Tseng, Wei Wen Su, Han Chieh Lin, Chun-Yen Lin, Chien-Hung Chen, Wen-Chih Wu, Ming Lun Yeh, Jia-Horng Kao, Chi Ming Tai, Chun-Jen Liu, Tzong Hsi Lee, Pei Lun Lee, and Lee Won Chong
- Subjects
medicine.medical_specialty ,Carcinoma, Hepatocellular ,Daclatasvir ,Sustained Virologic Response ,Sofosbuvir ,Viral Hepatitis ,Hepatitis C virus ,Taiwan ,Hepacivirus ,registry ,medicine.disease_cause ,Antiviral Agents ,Gastroenterology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Registries ,Treatment Failure ,DAA ,Hepatology ,business.industry ,Ribavirin ,Liver Neoplasms ,real world ,Hepatitis C, Chronic ,Middle Aged ,medicine.disease ,Hepatitis C ,CHC ,Treatment Outcome ,chemistry ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,HCV ,Coinfection ,Asunaprevir ,Original Article ,Drug Therapy, Combination ,Female ,030211 gastroenterology & hepatology ,business ,Viral load ,medicine.drug - Abstract
Background/aims Direct‐acting antivirals (DAAs) are highly effective in treating chronic hepatitis C virus (HCV)‐infected patients. The real‐world treatment outcome in Taiwanese patients on a nationwide basis is elusive. Methods The Taiwan HCV Registry (TACR) programme is a nationwide registry platform including 48 study sites, which is organized and supervised by the Taiwan Association for the Study of the Liver. The primary endpoint was sustained virological response (SVR12, undetectable HCV RNA 12 weeks after end‐of‐treatment). Results A total of 13 951 registered patients with SVR12 data available were analysed (mean age, 63.0 years; female, 55.9%; HCV genotype‐1 [GT1], 57.9%; cirrhosis, 38.4%; preexisting hepatocellular carcinoma [HCC], 10.6%; and hepatitis B virus coinfection, 7.7%). The overall SVR12 rate was 98.3%, with 98.7%, 98.0%, 98.4% and 97.4% in treatment‐naïve noncirrhotic, treatment‐naïve cirrhotic, treatment‐experienced noncirrhotic and treatment‐experienced cirrhotic patients, respectively. The SVR12 rate was > 95% across all subgroups except treatment‐experienced cirrhotic patients who received sofosbuvir/ribavirin (88.7%), treatment‐naïve noncirrhotic patients (94.8%) and treatment‐experienced cirrhotic (94.8%) patients who received daclatasvir/asunaprevir. The most important factor associated with treatment failure was DAA adherence
- Published
- 2021